Medimaps Group is a leading global medical software analytics company founded by a group of clinical practitioners and researchers, based in Switzerland with offices in the US and in France. It specializes in the engineering, research, development, and commercialization of medical software applications based on patented multi-purpose technologies.Its flagship product, the TBS iNsight™ (Osteo) software application has been used for years in over 75 countries in clinical practice to better predict fracture risk in the field of primary and secondary osteoporosis (e.g. in patients with diabetes, hyperparathyroidism, CKD, HIV, and GIO). The maximal impact of the TBS score is observed in patients with osteopenic BMD values who display low TBS scores and consequently have a higher combined risk profile; in patients whose fracture risk is close to the FRAX ® intervention thresholds; and in secondary osteoporosis. 